Chardan lowered the firm’s price target on Allurion Technologies to $2.50 from $5 and keeps a Buy rating on the shares following the Q2 report. The business continues to face a number of headwinds, the analyst tells investors in a research note. The firm says that while the business execution has been a disappointment over the past three quarters, it retains a bias that the company’s AUDACITY pivotal study will read out positive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies Faces NYSE Delisting Risk and Considers Remedies
- Allurion Technologies receives continued listing standards notice from NYSE
- Allurion Technologies reports Q2 EPS (5c), consensus (24c)
- ALUR Earnings this Week: How Will it Perform?
- Allurion Technologies Releases Informative Investor Presentation